Journal: Lung cancer (Amsterdam, Netherlands)
Article Title: Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
doi: 10.1016/j.lungcan.2021.03.018
Figure Lengend Snippet: Fig. 4. Concentrations of soluble CRT in plasma of NSCLC patients before and after the onset of treatment with cytotoxic agents or osimertinib. (A) The plasma concentration of soluble CRT was determined before (pre), on days 3 and 8 of, and after the end of the first cycle of chemo therapy with DTX (n = 12) or PEM (n = 4) in patients with advanced NSCLC. The maximum (max) value for soluble CRT observed after the onset of treatment was then compared with the corresponding baseline value. **P < 0.01 (Wilcoxon matched-pairs signed-rank test). (B) The plasma concentration of soluble CRT was determined before (pre), on days 3 and 8 of, and about 1 month after the onset of osimertinib therapy in patients with EGFR-mutated advanced NSCLC (n = 9). The maximum (max) value for soluble CRT observed after the onset of treatment was then compared with the cor responding baseline value. ***P < 0.001 (Wil coxon matched-pairs signed-rank test).
Article Snippet: Pemetrexed disodium (PEM) was obtained from LKT Laboratories; docetaxel (DTX), cisplatin (CDDP), and carboplatin (CBDCA) were from Tocris; gemcitabine (GEM) was from Tronto; and paclitaxel (PTX), vinorelbine ditartrate (VNR), dimethyl sulfoxide were from Wako, and Z-VAD-FMK was from Selleck.
Techniques: Clinical Proteomics, Concentration Assay